Five-year commercialisation activity at the university is on the rise in terms of patents, inventions and licensing revenue.

University endowment-backed Will Ventures aims to unlock sports-related innovation across markets such as fitness, media and gaming.

UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.

University of Wyoming-backed Momentus is set to merge with SPAC Stable Road Acquisition in a deal that values the space infrastructure company at $1.2bn.

Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.

Oxford's spinout portfolio raised a record-breaking $1.1bn during the past fiscal year and is now 204-companies strong.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

MIT's cancer therapy developer has set terms for an offering that will raise more than $185m if it floats at the top of its range.

10x Genomics has bought Harvard's genetic sequencing system provider and also revealed it closed its purchase of Stockholm University spinout CartaNA.

Ten startups will attend the Digital Forum as part of the university's Startup Challenge in partnership with GCV and Extreme Tech Challenge.